Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report.
Juliano Boufleur FarinhaLetícia Schwerz WeinertLidiane Pozza CostaMarcelo Zanusso CostaPatrícia Peres de PeresCláudia Fernandes LoreaPublished in: International journal of diabetes in developing countries (2022)
A patient with Prader-Willi syndrome (PWS), extreme obesity and hyperglycemia had her body weight increased considerably for 6 months, even with exercise and diet programs. Treatment with metformin and empagliflozin (12.5 mg/day) induced a weight loss of 14 kg (-10.3%) for 6 months and the reduction of glycated hemoglobin A 1c .
Keyphrases
- weight loss
- glycemic control
- growth hormone
- case report
- body weight
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- blood glucose
- type diabetes
- weight gain
- climate change
- diabetic rats
- physical activity
- insulin resistance
- public health
- metabolic syndrome
- high glucose
- drug induced
- body mass index
- combination therapy
- body composition
- stress induced